entertainment -WSS

entertainment

author：leisure time 2025-09-27 22:48:42 - browse：4

Insitro CEO and founder Daphne Koller Neilson Barnard/Getty Images for The New York Times

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

The very nature of the financials emphasize the exciting but risky reality: The technology has great promise, but nothing is guaranteed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Biogen walks away from Aduhelm, years after polarizing approval

hotspot

leisure time

hotspot

WSS

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Vertex non

Humana’s losses in Medicare Advantage tank its stock

Boston competes with Raleigh

Bernie Sanders is gearing up to subpoena pharma CEOs

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

hotspot

entertainment

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Medicare proposal to cover medical devices draws a mixed reaction

Medicare Advantage insurers face 0.2% cut to 2025 payments

In Memoriam: Notable people who died in 2023

Biogen walks away from Aduhelm, years after polarizing approval

Dobbs anniversary: the lost opportunity of abortion as health care

STAT Summit: Ending the crisis of Black deaths in the U.S.

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Venture capital firm's plans to take over Akron hospital face hurdles

focus

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Readout LOUD podcast: Live from the 2023 STAT Summit

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Zyn nicotine pouches become unlikely player in latest culture war

FDA clears Verve to begin U.S. study of gene

FDA clears Verve to begin U.S. study of gene

hotspot

leisure time

hotspot

explore